Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 13/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12828601 | 0.77 | ALDH1A1 (0.50) | NPSR1MAPTSMN1; SMN2ALDH1A1HTT | |
| SCHEMBL648813 | 0.69 | MLYCD (0.62) | MLYCD | |
| SCHEMBL15319936 | 0.69 | ALDH1A1 (0.73) | NPSR1SMN1; SMN2ALDH1A1LMNAHTT | |
| SCHEMBL7663247 | 0.68 | RECQL (0.64) | NPSR1MAPTSMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL11625535 | 0.68 | ALDH1A1 (0.76) | NPSR1MAPTSMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL4418772 | 0.68 | NPSR1 (0.63) | NPSR1MAPTSMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL12828886 | 0.67 | NAMPT (0.48) | MAPTSMN1; SMN2ALDH1A1LMNAHTT | |
| SCHEMBL7082686 | 0.67 | TSHR (0.73) | NPSR1MAPTSMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL9130703 | 0.66 | FES (0.81) | NPSR1MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL29460250 | 0.66 | FES (0.81) | NPSR1MAPTSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119819-B2 | Malonyl-CoA decarboxylase inhibitors useful as metabolic modulators | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-02-21 | — | — | US | claimed |
| EP-1411929-B1 | MALONYL-COA DECARBOXYLASE INHIBITORS USEFUL AS METABOLIC MODULATORS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2011-05-11 | — | — | EP | claimed |
| US-20100016259-A1 | Malonyl-CoA Decarboxylase Inhibitors Useful as Metabolic Modulators | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-01-21 | — | — | US | claimed |
| JP-2004527475-A | — | — | 2004-09-09 | — | — | JP | claimed |
| US-20040082576-A1 | Malonyl-coa decarboxylase inhibitors useful as metabolic modulators | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-04-29 | — | — | US | claimed |
| EP-1411929-A2 | MALONYL-COA DECARBOXYLASE INHIBITORS USEFUL AS METABOLIC MODULATORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-04-28 | — | — | EP | claimed |
| WO-2002058698-A2 | MALONYL-COA DECARBOXYLASE INHIBITORS USEFUL AS METABOLIC MODULATORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-08-01 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016259-A1 | Malonyl-CoA Decarboxylase Inhibitors Useful as Metabolic Modulators | MLYCD, ME3, ACACA | MLYCD 1/4885NPSR1 4820/4885MAPT 1917/4885 |
| US-20040082576-A1 | Malonyl-coa decarboxylase inhibitors useful as metabolic modulators | MLYCD, ME3, ACACA | MLYCD 1/4885NPSR1 4820/4885MAPT 1917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.